Everyone should remember that (as has been stated in the Hunter Hall video clip) a vaccine and an antiviral are two very different things. A vaccine will only be effective for the strain of flu that it has been designed for. An antiviral is generally effective for most if not all flu variants. If GSK develop a vaccine, then that one strain slice of the market will be the only potential impact to Relenza/Tam sales.
Unfortunately for flu sufferers, viruses mutate and sometimes quickly. Fortunately for Biota share holders, that fact plus the fact that there are 000s of strains of flu will keep Relenza and no doubt Lani is high demand for a long time to come.
I'm interested to know what deal and with whom Biota will have for Lani. Perhaps they can do a better job of marketing and pushing new sales of Lani when it hits the market than has been done for Relenza.
I'm very optimistic for Biota's future, especially with Lani, but even without.
BTA Price at posting:
$1.88 Sentiment: LT Buy Disclosure: Held
